Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm thinking halted or suspended tomorrow
Yupp!
Dilution or delusion?
There's no buyers.
They are in California. The Nevada address is the old company.
Where'd they move to?
My point is, is that you are either in at .001 (on average) and are praying and hoping this thing goes or you are a total BullSh*t artist.
Either way I feel sorry for you that you have to keep PUMPING this.
You probably have a few Million Shares at .001 and hate to lose you $500.00.
I wouldn't blame you. I wouldn't want to lose $500.00 either.
STOP with the BULLSH*T.
Come CLEAN!
If you have 36 Million Shares, I understand why you PUMP this.
Based on your posts you are in at .015. POOR LOSER.
Come clean now and we will all give you our support.
I know I will. I never like seeing anyone lose money.
Reply to that...Or do you want me to back further???
Let me remind you of NOT too long ago...
KngmAz Thursday, 12/10/15 05:24:38 PM
Re: SilentSniper post# 2019
Post #
2020
of 4464 Go
I added another 575,000 shares of ACTL stock today and I am just absolutely LOVEN-IT!! I've added over THREE MILLION (3,000,000) additional shares of ACTL stock in just the past few days. MERRY CHRISTMAS TO ME!!
Such BullS*tt
KngmAz, if you have all the shares you say over the period you say, you are going to take a loss of 50G's EASY. Maybe 100 grand.
If you really have what you have, share the prices and shares you are in at.
Won't happen.
If indeed you have what you say you have, I feel sorry for you.
On the other hand, if you have what you say you have, I hope you do indeed get out at least at a break even. Not wishing you any harm or loss.
And that's a good thing?
Usually means more sellers then buyers...
Can't bonce much lower...LOL
Truth?
I hope you guys/girls are right but every day the price goes down.
I stated facts with the filings yet my post was taken down. Why?
In connection with the Credit Facility, the Company granted the lender a first priority security interest in all of the Company's assets.
Who wipes out my POSTS anyway? I never write anything I don't think is right, In my opinion...
If my posts are deleted again I will post every hour the same Post.
I hope you guys make $$$$ but I see this as a dead end and only want to give my opinion so others don't get burnt investing.
I can answer that question.
In the filing on December 31st it says, "In connection with the Credit Facility, the Company granted the lender a first priority security interest in all of the Company's assets."
The bottom will be NO BID.
.0002...No, No, this is the bottom...LOL
Good write off
I think this is the bottom...LOL
And they will.
I hope you are right.
Good Luck.
Good Luck!
I feel for you.
Read the financials and look at the volume.
Either you are trying to PUMP a little (which I can understand) or you are as dumb as they come.
Additionally, explain to me why you or your "ppl" would file a 13g?
97 million shares on Thursday.
Does that not tell everyone anything?
That would be half the O/S.
How would that be possible?
Shares are increasing every 10 days.
Notes are Hundreds of Thousands.
IMO, get out while you can.
I hope everyone sees a BOUNCE and gets out then but I see this going NO BID.
The last filing said that if the "lender" didn't make their money, they get all assets of The Company. (The Shell)
Hopefully Monday it pops but the East Coast is going to be buried.
GO ACTL,
From your friend in Santa Barbara.
More delusion coming...Just look at the volume.
I hope it bounces for those that want to get out but this ain't looking good. Look at the filings.
Hundreds of thousands in convertibles.
Again, I hope you all the best but....
OY Vey... Scary...
Do you people realize this keeps going down day after day, week after week, Month after Month?
Perhaps its time to get out at a loss than lose everything?
I hope I'm wrong for all those invested but that's what I see.
This is just gambling...
Everyone looking to break .0013 and now it was down to .0007.
Everyone saying it was the LOW, Everyone said that at .01
Do people actually believe this or are they HIGH?
Are they PUMPERS to hope others buy or BELIEVERS? Just curious?
Your thoughts?
I have no skin in the game but wonder why people think this might jump?
Perhaps I might get in based on some rational thoughts.
Please let me know your thoughts.
Thanks
What is the legal problem?
You can't get much lower...
That's what I was thinking...
You'd think it would at least go up somewhat, if not pretty well...NO?
I saw it on FOX in NY...
Half-Year Update Provides Insight into Accelerating Pace of Developments
SAN MARINO, Calif., July 20, 2011 /PRNewswire via COMTEX/ -- Viral Genetics, Inc. (Pinksheets: VRAL) is providing this update of accomplishments and highlights from the first half of the year.
"We've made fundamental advancements implementing the company's strategic plan in the past six months," said Haig Kaledjian, CEO. "The hard work of our research scientists, our advisory board members and our corporate staff is now beginning to bear fruit as we experience an accelerating pace of developments in all areas of the business. The following overview provides some insight into these accomplishments and our future direction."
Enhanced Shareholder Communications: On August 3 at 4:30PM EDT, the Company will hold a corporate presentation via webcast to review recent and ongoing developments at Viral Genetics and VG Energy. Questions may be submitted by email to info@viralgenetics.com for consideration for inclusion during the Q&A portion of the presentation. Additionally, the Company website, www.viralgenetics.com, now includes the most recent corporate presentation and quarterly fact sheet for viewing and downloading. Individuals are also encouraged to subscribe to the Company's email list via www.viralgenetics.com to receive regular updates.
Ongoing Research Coverage: In 2011, the Company arranged for two new providers of issuer-paid research, Research 2.0 and Zacks Small Cap, to join Institutional Analyst in providing professional quality research reports covering Viral Genetics and its VG Energy subsidiary. The Research 2.0 and Zacks reports are available on the Company website, www.viralgenetics.com.
HIV/AIDS Program: In early 2011, the Company received feedback from the US FDA on its pre-IND for its HIV/AIDS drug program, APi1177. Furthermore, the company is now completing the securing of a long-term manufacturing relationship for its clinical-grade drug (GLP and GMP). We intend to proceed with in vitro tests as well as animal safety and toxicity studies which are required by the FDA prior to clinical trials in humans. We expect to file the full IND for APi1177 within 3-6 months, contingent on funding and completion of testing.
Lyme Disease Program: The Company is in the process of completing its pre-IND for the Lyme Disease drug program. A clinical investigator is now being recruited who will assist in completing the clinical design aspects of the pre-IND.
Awards: Company chief scientific advisor, M. Karen Newell-Rogers, PhD, and advisor, Richard Gerstner, were recently honored for their contributions to Lyme Disease research by Tyme for Lyme, a non-profit organization dedicated to eradication of tick-borne illnesses. The awards were presented at a gala black tie event in New York City.
Drug-Resistant Cancer Program: The investigator study of the Company's Metabolic Disruption ("MDT") compounds for treatment of drug-resistant cancers at Scott and White Hospital is undergoing Institutional Review Board review. The Company expects that this study will commence this summer, with approximately 12 months of follow up. The study was funded by an anonymous grant of $1.5 million to Scott and White, specifically directed to the study
"Our VG Energy subsidiary continues to exceed our expectations as a significant advancement in the algal bio-fuel sector. The algal bio-fuel segment of the alternative energy markets is garnering the largest share of institutional, VC and corporate investment dollars in the bio-fuel market, and is seen as the economically viable alternative to petroleum based fuels. We are pursuing several pathways for commercialization of VG Energy's technology," continued Mr. Kaledjian.
VG Energy - Industrial Scale Testing: Viral Genetics' majority-owned subsidiary, VG Energy, successfully completed the first phase of an independent industrial-scale demonstration of MDT lipid-enhancing compounds, which resulted in significantly increased yields of oils from algae. The second phase of this testing is dose response analysis, which examines whether manipulation of different quantities of MDT compounds can further enhance yields. Once this portion of testing is complete, it will be followed by industrial scale testing in a closed bioreactor algae-cultivation environment. Final results of this testing are expected within 2-3 months.
VG Energy - Other Testing: VG Energy is also completing testing of MDT compounds on various additional strains of algae and different processes. These tests include algae used in open pond or raceways (a circular configuration for moving nutrients and water through the algal growth pools); "reversing" the lipid-enhancing properties of MDT to increase glucose rather than oils, which reduces the steps needed to convert the algal product to a usable fuel; and testing MDT compounds on yeast used for production of omega-3 fatty acids.
VG Energy - Partnering Efforts: VG Energy is actively engaged in exploring strategic partnerships and business relationships including, but not limited to, licensing or collaborative research relationships with leading firms and academic institutions for the purpose of achieving commercialization and/or developing new applications of MDT compounds in energy, food, cosmetics and nutriceuticals.
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.
About VG Energy
VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit www.vgenergy.net.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.'s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.
Contact: Haig Keledjian, Viral GeneticsT: (626) 334-5310Email: info@viralgenetics.com
SOURCE Viral Genetics, Inc.
www.prnewswire.com
VRAL Research 2.0 Update
Here are the highlights from the first page:
It has been a long and winding road for Viral Genetics, as a major lawsuit threatened the company’s very existence. A recent litigation settlement has cleared the way for the company to move back into clinical testing on its core drug compounds after a five year hiatus. Additionally, a new dynamic has been introduced into the value-creation equation for Viral Genetics with the launch of its majority owned subsidiary, VG Energy.
Viral Genetics is developing drugs based on its patented and proprietary Targeted Peptide and Metabolic Disruption technologies aimed at large end markets, including HIV/AIDs, drug-resistant cancer and Lyme disease. The year ahead promises to be a busy one, with Viral planning on beginning Phase 1 testing of its APi1177 drug for HIV/AIDS and VGV-L drug for Lyme. In addition, the company expects to begin an investigators study on its MDT drug-resistant cancer drug at Scott & White Hospital in Temple, Texas.
Over the past year, we’ve seen growing interest among established companies and investors in companies such as Solazyme (SZYM) who are able to profitably produce oils from algae for use as fuels, chemicals, nutritionals and skin and personal care products. VG Energy’s Metabolic Disruption technology has demonstrated impressive results in the lab with an improvement in oil yields in algae of at least 300%. Preliminary analysis shows that its additives offer the ability to knock down the cost of algal oil production by almost a factor of ten as a result of productivity improvements. This cost improvement is on a par with what Solazyme has done over the past several years with its unique “indirect photosynthesis” technology process.
VG Energy is working with alternative energy producer BioProcess Algae to verify lab results on a large scale for the development of commercial production of its potential biofuel process in closed bioreactors. Initial test results are favorable and further testing is planned this summer. VG Energy is aggressively exploring commercial licensing opportunities of its technology with established and emerging energy, chemicals, and food companies.
Our base case financial model of Viral Genetics, excluding VG Energy, values the shares at $0.50 in 2012. The base case scenario assumes Viral is successful in raising the $2 to $3 million in funding this year necessary for clinical testing of its core drugs and VG Energy products. We have also developed a base case valuation model for VG Energy, which we expect to become a larger and more important source of value creation for Viral Genetics in the months ahead.Our financial analysis of VG Energy shows significant value-creating potential given the large target markets that collectively exceed over one trillion dollars. Our base case estimate of the value of VG Energy boosts the intrinsic value of Viral Genetics in 2012 to $1.30/share.
SLTZ News Release May 17, 2011 08:00 ET
Solar Thin Films, Inc. Discusses 2011
NEW YORK, NY--(Marketwire - May 17, 2011) - Solar Thin Films, Inc. (PINKSHEETS: SLTZ) reflects on the present year and changes moving forward.
Solar Thin Films, Inc. (the "Company") has changed its business from its discontinued operations with respect to the sale of turnkey factories for the production of thin film solar modules to concentrate on establishing, financing, managing and syndicating solar farms as power projects both domestically and internationally. The Company plans to change the name of Solar Thin Films, Inc. to one which better defines its new direction.
Solar Thin Films, Inc. is presently in preliminary negotiations on projects both domestically and internationally and should have additional updates in the near term.
For the Full Press Release please go here: http://www.marketwire.com/press-release/solar-thin-films-inc-discusses-2011-pinksheets-sltz-1515307.htm
New ActiveCare Technology Enables Seniors to Remain Independent
ActiveHome Monitoring System Ready To Market
SALT LAKE CITY, April 15, 2011 /PRNewswire via COMTEX/ -- ActiveCare, Inc. (ACAR.OB) a leader in senior care technology, today announced the introduction of its' ActiveHome(TM) Monitoring System which has been two years in the making. This technology combined with ActiveCare's mobile care service that assists seniors 24/7 no matter where they may be, allows seniors to live an independent yet safe lifestyle with their medical and everyday needs being met 24/7.
"We are excited with ActiveCare's introduction of the ActiveHome(TM) Monitoring System which will allow us to better take advantage of an estimated $17 billion market that is emerging over the next ten years," said Jim Dalton, Chairman and CEO of ActiveCare.
Providing a continuum of care and protection, the ActiveHome system comprises of a combination of smart home, health and well being technology that sends vital data to the Company's CareCenter. The CareCenter is able to monitor whether a member takes their medication, skips a meal, or is sick in bed. CareSpecialists act as personal assistants, reminding them to take medication, arranging for grocery and meal delivery as well as other care services. Through smart home technology members are able to turn out all the lights in the house and lock the door all with the press of one button, placed beside the bed. Likewise CareSpecialists are able to monitor and control lights, locks and even the stove remotely.
"While every member has different struggles, there is one unifying desire to 'age in place.' Our products and services allow members to age with dignity, while providing the peace of mind to loved ones and caregivers," continued Dalton.
ActiveCare's products are designed to enhance member's lifestyle and safety both at home and on the go. Through the Company's PAL (Personal Assistance Link) technology, CareSpecialists are able to track members' location and provide needed assistance no mater where they may be. The combination of mobile and in home technology provides a complete level of care, fulfilling the needs of the growing senior marketplace.
About ActiveCare:
ActiveCare, Inc., (www.activecare.com) is the service leader in care for the elderly, disabled or chronically ill providing deserved freedom while allowing members to remain living independently longer. The ActiveCare solution incorporates sensor technologies that allows a member to be constantly monitored in their own home and on the go. Inside the member's home, ActiveCare installs sensors that allows ActiveCare's 24/7 CareCenter(TM) to monitor their movements and health conditions. When the CareCenter(TM) detects any type of anomaly it can immediately contact the member through a body worn watch device, the ActiveWatch(TM) or through the ActivePortal(TM), a video portal located in the senior's home. This video portal allows live video interaction between the member and the CareSpecialist(TM) - providing a personal and bonding experience. The CareCenter(TM) can remotely monitor the member's eating habits with sensors on the stove, refrigerator and cabinets. The CareSpecialist(TM) can also monitor the medications the senior is taking and insure that they are taking the right medications at the right time - all through ActiveCare's sensor technologies. In addition, the CareCenter can track vital signs such as heart rate, blood pressure, weight and glucose levels. It can also monitor how long the member has been in bed or in a chair and can assist in turning on and off lights and locking or unlocking doors.
When the members are on the go away from their home, they can be tracked through ActiveCare's GPS technology. Through the ActiveWatch(TM) or ActiveOne+(TM) PAL members can instantly contact a CareSpecialist(TM) with the press of a button or automatically when a fall occurs.
Headquartered in Salt Lake City, Utah, ActiveCare is committed to providing consistent excellence in quality and safety as well as friendly care for members and caregivers, alike. To learn more about ActiveCare, Inc. visit www.activecare.com or contact investor/media relations at 877-219-6050.
SOURCE ActiveCare, Inc.